Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction
Brad Moriyama(National Institutes of Health Clinical Center), Thomas J. Walsh(Cornell University), Caroline Jjingo(National Institute of Allergy and Infectious Diseases), Wyndham H. Wilson(National Institutes of Health), Xuan Huang(Sun Yat-sen University), Stacey A. Henning(National Institutes of Health Clinical Center), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Janice M. Leung(National Institutes of Health Clinical Center), Scott Penzak(National Institutes of Health Clinical Center)
Cited by 19
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k